Skip to main content

Table 2 Clinicopathological Characteristics and TP53 Mutational Analysis

From: TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer

Characteristics Number of total patients (%) Pc Number of TP53 Mutations (%) Pd
Parity    0.019*    0.042*
 0-1 77 47.8   59 48.0  
 2-3 66 41.0   57 46.3  
 >3 15 9.3   7 5.7  
Peritoneal metastasis    0.004*    0.027*
 yes 89 55.3   79 64.2  
 no FIGO stage 71 44.1 0.025* 44 35.8 0.024*
 I 55 34.2   33 26.8  
 II 18 11.2   17 13.8  
 III 80 49.7   66 53.7  
 IV 7 4.3   7 5.7  
Histotype    0.954    0.114
 serous 91 56.5   70 56.9  
 mucinous 22 13.7   16 13.0  
 endometrioid 23 14.3   13 10.6  
 clear cell 16 9.9   15 12.2  
 undifferentiated 9 5.6   9 7.3  
WHO grade    0.415    0.068
 G1 33 20.5   22 17.9  
 G2 57 35.4   39 31.7  
 G3 69 42.9   62 50.4  
Tumor gradea    0.003*    0.002*
 low-grade 57 35.4   33 26.8  
 high-grade 101 62.7   90 73.2  
CA125 (Uml–1) b    0.001*    0.508
  ≤ 206.52 86 53.4   51 41.5  
  > 206.52 46 28.6   39 31.7  
Residual tumor (cm)    <0.0001*    0.102
  ≤ 0.5 119 73.9   86 69.9  
  > 0.5 40 24.8   37 30.1  
Platinum resistance    <0.0001*    0.161
 yes 36 22.4   33 26.8  
 no 123 76.4   90 73.2  
  1. a: In accordance with morphological and molecular genetic analysis, EOC was divided into two categories [28]
  2. b: Based on patient survival, the cutoff value of CA125 calculated with a receiver operating characteristic (ROC) was 206.52 (Uml–1)
  3. c: p value for clinicopathological characteristics
  4. d: p value for TP53 mutation
  5. *p < 0.05